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interacts with integrin β1 and regulates its
phosphorylation at tyrosine 783
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Background: Phosphatase of regenerating liver-3 (PRL-3 or PTP4A3) has been implicated in controlling cancer cell
proliferation, motility, metastasis, and angiogenesis. Deregulated expression of PRL-3 is highly correlated with cancer
progression and predicts poor survival. Although PRL-3 was categorized as a tyrosine phosphatase, its cellular
substrates remain largely unknown.
Results: We demonstrated that PRL-3 interacts with integrin β1 in cancer cells. Recombinant PRL-3 associates with
the intracellular domain of integrin β1 in vitro. Silencing of integrin α1 enhances PRL-3-integrin β1 interaction.
Furthermore, PRL-3 diminishes tyrosine phosphorylation of integrin β1 in vitro and in vivo. With site-specific
anti-phosphotyrosine antibodies against residues in the intracellular domain of integrin β1, tyrosine-783, but not
tyrosine-795, is shown to be dephosphorylated by PRL-3 in a catalytic activity-dependant manner. Phosphorylation
of Y783 is potentiated by ablation of PRL-3 or by treatment with a chemical inhibitor of PRL-3. Conversely,
depletion of integrin α1 decreases the phosphorylation of this site.
Conclusions: Our results revealed a direct interaction between PRL-3 and integrin β1 and characterized Y783 of
integrin β1 as a bona fide substrate of PRL-3, which is negatively regulated by integrin α1.
Keywords: PRL-3, tyrosine phosphatase, integrin β1, dephosphorylationBackground
PRL-3, a non-receptor tyrosine phosphatase containing a
CAAX motif for prenylation at the carboxyl terminus
[1], was found to be up-regulated in various types of ma-
lignancy, including colorectal, gastric, ovarian and breast
cancers [2-5]. It has been shown to play a causal role in
tumor metastasis by enhancing cancer cell motility and
in tumor angiogenesis by recruiting endothelial cells [2].
PRL-3 expression is correlated with disease progression
and poor survival [3-8], and its antibody was shown to
dramatically inhibit metastatic tumor formation in
human ovarian cancer cells [9], therefore it had been* Correspondence: scc@bjcancer.org
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reproduction in any medium, provided the ordeemed as a potential therapeutic target for the treat-
ment of cancer [10].
PRL-3 could down-regulate PTEN expression and acti-
vate the PI3K pathway to promote epithelial-mesenchymal
transition (EMT), thus contributing to tumor metastasis
[11]. It has been implicated in controlling integrin-Src sig-
naling pathway, in which ectopic PRL-3 promoted Src acti-
vation and potentiated Src-modulated oncogenic pathways,
including ERK1/2, STAT3, and p130Cas [12]. PRL-3 was
also shown to be a negative regulator of tumor suppressor
p53 [13]. As a phosphatase, few PRL-3 substrates had been
characterized, including Ezrin [14] and cytokeratin 8 [15],
however, the cellular substrates of PRL-3 remain largely
unknown.
Integrins are a large family of trans-membrane pro-
teins, which are broadly involved in regulation of cell ad-
hesion, motility and other physical and pathological
processes [16,17]. Engagement of intergrins with their
ligands stimulates diverse intracellular signaling path-
ways, such as tyrosine phosphorylation and activation of. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and β1 are known to heterodimerize to form the recep-
tor for extracellular matrix (ECM), which is prerequisite
for downstream signaling [17]. We previously identified
integrin α1 as an interacting protein of PRL-3 through
yeast two-hybrid screening, and PRL-3 could down-
regulate the tyrosine-phosphorylation level of integrin
β1 [20]. Furthermore, we showed the critical role of in-
tegrin β1-ERK1/2-MMP2 signaling in PRL-3-promoted
motility, invasion, and metastasis of colon cancer cells
[21]. In this study, we demonstrate that PRL-3 directly
binds to integrin β1 and dephosphorylates integrin β1-
Y783, a key residue for integrin β1 function [22]. More-
over, we show that integrin α1 inhibits the PRL-3/integrin
β1 interaction and the dephosphorylation of integrin β1-
Y783 by PRL-3.
Results
Direct interaction between PRL-3 and integrin β1, which
is regulated by integrin α1
Our previous findings of integrin α1 as a binding partner of
PRL-3 [20] and integrin β1-ERK1/2-MMP2 signaling medi-
ating PRL-3-promoted cell invasion and metastasis [21]
prompted us to further dissect the relationship between
PRL-3 and integrins. As an initial step, we examined theirFigure 1 Physical interaction between PRL-3 and integrin β1. (A) The
lines. Equal amount of protein lysates from indicated cells were subjected
GAPDH protein expression was shown as loading control. (B) Endogenous
BGC823 (left panel) or SW480 (right panel) cells were immunoprecipitated
(control), followed by Western blotting with integrin β1 and PRL-3 antibod
shown as input. (C) Direct interaction between PRL-3 and integrin β1. GST-
were expressed respectively and used for in vitro pull-down assay.expression levels in human gastric cancer cell line BGC823
and colon cancer cell lines SW480, LoVo, and HCT116.
Figure 1A shows that integrin β1 was expressed in all these
cell lines, but integrin α1 was only detected in BGC823
cells. In addition, relatively high expression of PRL-3 was
found in BGC823 and SW480 cells (Figure 1A). Next, co-
immunoprecititation assay was performed with protein
lysates from BGC823 cells and SW480 cells. In both cell
lines, endogenous integrin β1 was detected in anti-PRL-3
precipitates (Figure 1B). Furthermore, GST pull-down assay
was performed with bacterially expressed His-tagged PRL-3
and GST-fused intracellular domain of integrin β1 (752-
798aa). The result shows that His-PRL-3 could be precipi-
tated by GST-intergrin β1, but not by GST (Figure 1C).
Thus, PRL-3 directly interacts with integrin β1.
Since integrin α1 heterodimerizes with integrin β1 [16]
and our previous study revealed an integrin α1-PRL-3
interaction [20], we then investigated whether integrin
α1 plays a role in modulating PRL-3-integrin β1 inter-
action. We transfected integrin α1-specific siRNA or
control siRNA into integrin α1-proficient BGC823 cells,
and performed co-immunoprecipitation assay. As shown
in Figure 2A, more integrin β1 was precipitated by anti-
PRL-3 antibody upon integrin α1-silencing. In addition,
we carried out immunoflorescence assay to examine theexpression profiles of integrin β1, integrin α1 and PRL-3 in different cell
to Western blotting with integrin β1, integrin α1and PRL-3 antibodies.
interaction between PRL-3 and integrin β1. 500 μg of lysates from
with 1 μg PRL-3 monoclonal antibody or 1 μg pre-immune mouse IgG
ies. Expression of integrin β1 and PRL-3 in the lysates (50 μg) was
integrin β1 (intracellular domain, 752-798aa) and His-tagged PRL-3
Figure 2 Physical interaction between PRL-3 and integrin β1. (A) Deletion of integrin α1 resulted in enhanced PRL-3-integrin β1 interaction.
BGC823 cells were transfected with 100 pmol integrin α1-specific siRNA or control siRNA for 48 hr. 500 μg protein lysates were incubated with
PRL-3 antibody or pre-immune mouse IgG (control) for co-immunoprecipitation assay. The immunoprecipitates and 50 μg protein lysates (input)
were immunoblotted by integrin β1 and PRL-3 antibodies. Efficiency of intergrin α1 silencing in the input was verified. “LC” is short for light chain
of antibody. (B) PRL-3 co-localized with integrin β1 in an integrin α1-independent manner. After being transfected with 100 pmol integrin α1
siRNA and control siRNA for 24 hours, BGC823 cells were transfected with 2 μg GFP-PRL-3, and cultured for another 24 hours, then fixed, blocked,
and immunostained with anti-integrin β1 antibody. Localization of GFP-PRL-3 (green) and integrin β1 (red) was detected by a laser confocal
microscope. Parts of merged images were enlarged (white rectangles) to show the co-localization between two molecules (yellow). The white
arrows labeled regions were further enlarged (insert).
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tegrin β1. GFP-PRL-3 and integrin β1 partially co-
localized on the punctate structures of cell membrane in
control siRNA-transfected cells. However, knockdown of
integrin α1 resulted in an increase in the co-localization
between GFP-PRL-3 and integrin β1 (Figure 2B). These
findings suggest that integrin α1 negatively regulates as-
sociation between PRL-3 and integrin β1.
In vitro and in vivo dephosphorylation of integrin β1 by
PRL-3
Since PRL-3 directly interacts with integrin β1, we further
investigated if integrin β1 is a substrate of PRL-3
phosphatase. We expressed and purified GST-fused wild-type PRL-3 and the PRL-3-mt, in which the phosphatase
activity was eliminated by mutating cystine 104 to serine
[12,23] (Figure 3A). In vitro dephosphorylation assay was
performed with GST-PRL-3 and GST-PRL-3-mt plus
equal amount of immunoprecipitated endogenous integrin
β1 as substrate. We found wild-type GST-PRL-3 signifi-
cantly decreased the tyrosine phosphorylation of integrin
β1, whereas mutant GST-PRL-3 had no obvious effect
(Figure 3B).
Moreover, we examined if such regulation occurs
in vivo. We introduced myc-PRL-3 into BGC823 and
HCT116 cells. As controls, the cells were transfected
with vector alone. Immunoblot analysis revealed that ec-
topic expression of myc-PRL-3 considerably decreased
Figure 3 In vitro and in vivo dephosphorylation of integrin β1 by PRL-3. (A) The purified GST-PRL-3, mutant GST-PRL-3 (GST-PRL-3-mt) and
GST proteins were examined by SDS-PAGE and commassie blue staining. (B) Dephosphorylation of integrin β1 by PRL-3 in vitro. 1000 μg HCT116
cell lysates were immunoprecipitated with integrin β1 antibody or control IgG. After sequential washing with lysis buffer and dephosphorylation
buffer, the precipitates were used as substrates, and incubated with 1 μg purified GST-PRL-3 wt, GST-PRL-3 mt or GST in the dephosphorylation
buffer for 30 min at 30°C, then the mixtures were analyzed by Western blotting with anti-phosphotyrosine (4G10) and anti-integrin β1 antibodies.
(C) Dephosphorylation of integrin β1 in HCT116 (left panel) and BGC823 (right panel) cells by ectopic expression of PRL-3. Equal amount of
lysates from cells over-expressing myc-PRL-3 and pcDNA3 (control) were immunoprecipitated with anti-phosphotyrosine (4G10) antibody,
followed by immunoblotting with anti-integrin β1 antibody. Expression of integrin β1 and myc-PRL-3 in the lysates were indicated.
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but did not affect total protein levels of integrin β1
(Figure 3C). These results indicate that PRL-3 depho-
sphorylates integrin β1 in vitro and in vivo.
PRL-3 dephosphorylates tyrosine-783 of integrin β1
Previous study reported that phosphorylation of Y783
and/or Y795 in the cytoplasmic domain of integrin β1
may be essential for its function [24]. We next investi-
gated whether PRL-3 dephsohorylates Y783 and/or
Y795. BGC823 cells and SW480 cells were transfected
with myc-tagged wild-type PRL-3 and PRL-3-mt.Immunoblot analysis revealed that ectopic expression of
PRL-3, but not PRL-3-mt, significantly reduced pY783 of
integrin β1 in both cell lines (Figure 4A), while pY795
were undetectable (data not shown). We also knocked
down endogenous PRL-3 and found that depletion of
PRL-3 could markedly increase pY783 levels in BGC823
cells (Figure 4B). To further validate PRL-3-mediated
dephosphorylation of Y783 of integrin β1, chemical in-
hibitor of PRL-3 (P0108), which has been shown to spe-
cifically inhibit PRL-3 phosphatase activity and decrease
PRL-3-mediated cancer cell migration and invasion
[15,25], was used to treat BGC823 and SW480 cells.
Figure 4 Regulation of integrin β1 phosphorylation at tyrosine 783 by PRL-3. (A) Wild-type myc-PRL-3, but not mutant myc-PRL-3
dephosphorylated tyrosine 783 of integrin β1 in BGC-823 (left panel) and SW480 cells (right panel). After transfection with myc-PRL-3, myc-PRL-3-
mt or pcDNA3 (control) plasmids, equal amount of cell lysates were analyzed by Western blotting with antibodies against pY783, integrin β1, myc
and GAPDH. (B) Knockdown of PRL-3 promoted pY783 phosphorylation. BGC823 cells were transfected with 100 pmol indicated siRNA for 48
hours, and the cell lysates were analyzed by Western blotting with indicated antibodies. (C) PRL-3 inhibitor enhanced pY783 phosphorylation.
BGC823 (left panel) and SW480 cells (right panel) were treated with 10 μg/ml PRL-3 inhibitor. Cells were harvested at different time points and
protein lysates were analyzed by Western blotting with indicated antibodies. (D) PRL-3 had minimal effect on pY795 of integrin β1. BGC823 (left
panel) and SW480 cells (right panel) were treated with 10 μg/ml PRL-3 inhibitor or 100 μM provanadate (as positive control). Protein lysates were
harvested at indicated time points and analyzed by Western blotting. (E) Knockdown of integrin α1 decreased pY783 phosphorylation. BGC823
cells were transfected with integrin α1-specific siRNA or control siRNA for 72 hours, and the lysates were analyzed by Western blotting.
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observed after P0108 treatment (Figure 4C). P0108 had
a marginal stimulatory effect on pY795 in BGC823 cells,
but pY795 could be strongly enhanced by treatment with
tyrosine phosphatase inhibitor pervanadate in both
BGC823 and SW480 cells (Figure 4D). In line with
enhanced PRL-3-integrin β1 interaction upon silencing
of integrin α1 (Figure 2A and B), pY783 was decreased
by ablation of integrin α1 (Figure 4E). Collectively, these
results show that PRL-3 dephosphorylates integrin β1 at
tyrosine-783, but not tyrosine-795.
Discussion
Protein kinases and phosphatases play important roles in
diverse physiological processes and diseases [26-28].
PRL-3, as a member of protein phosphatases, has been
found to promote cancer cell invasiveness [10,29-32].
However, the underlying mechanism remains elusive. In
the present study, we demonstrate that PRL-3 directly
binds to integrin β1 and dephosphorylates integrin β1-
Y783. Furthermore, we found that deletion of integrin
α1 resulted in increased PRL-3-integrin β1 association
and decreased phosphorylation of integrin β1-Y783.
These findings indicate that integrin β1 is a bona fide
substrate of PRL-3 and raise the possibility that integrin
α1 may function as a negative regulator for PRL-3-
integrin β1 interaction.
Previous studies have shown that integrin β1-Y783 and
-Y795 are parts of conserved NPxY motifs essential for
recruiting talin and kindlin, which in turn facilitates
coupling of integrin β1 to the actin cytoskeleton and
maintains integrins in an active signaling state [33]. It
was reported that v-Src could phosphorylate integrin β1
tails on Y783 and Y795 [34,35], and that phosphorylated
Y783 and Y795 could block talin and kindlin’s binding
with integrin β1, respectively [36,37]. These were sup-
ported by the study that v-Src expression in fibroblasts
decreases integrin β1–dependent adhesion, focal adhe-
sion formation, cytoskeletal organization, fibronectin
assembly, migration, and chemotaxis [34,38]. While sev-
eral kinases, including Src, have been shown to phos-
phorylate Y783 and Y795 [34,35], the phosphatase(s)
catalyzing the de-phosphorylation of these two sites is
unknown. By showing PRL-3 is responsible for depho-
sphorylating pY783, our present results provide an ex-
planation for the delicate control of integrin β1.
It is noted that a recent study showing the short
phosphotyrosine peptides encompassing Y783 or Y795
of integrin β1 could not be dephosphorylated by PRL-3
in an in vitro assay [39]. However, as the author sug-
gested, this could be explained by lack of entire integrin
β1 to be recognized by PRL-3 [39]. In our study, instead
of using the synthesized peptides, we immunoprecipited
the endogenous integrin β1 as substrate for in vitrophosphatase assay, which ensures optimal phosphatase-
substrate association. In addition, we did not find alter-
ation in pY795 by over-expression or ablation of PRL-3,
which could be due to the fact that pY795 level is too
low to be detected in the cancer cells examined. We did
observe slightly more pY795 in PRL-3 inhibitor treated
BGC823 cells, while such agent-induced changes of
pY795 was not as robust as those of pY783 in BGC823
and SW480 cells. Interestingly, treatment with a pan-
phosphatase inhibitor significantly elevates pY795, sug-
gesting that PRL-3 may partially contribute to the
dephosphorylation of pY795 and pY795 is mainly regu-
lated by other phosphatase(s).
Conclusion
In summary, our results demonstrated a direct inter-
action between PRL-3 and integrin β1, which could be
negatively regulated by integrin α1. Importantly, we
identified tyrosine 783 of integrin β1 as a direct depho-
sphorylation site by PRL-3, thus uncovering the first
tyrosine phosphorylation site to be regulated by PRL-3
phosphatase.
Methods
Cell lines and Reagents
Colon cancer cell lines LoVo, SW480 and HCT116 were
obtained from ATCC (Manassas, VA) and maintained in
DMEM (Invitrogen, Carlsbad, CA). Gastric cancer cell
BGC823 was maintained in RPMI-1640 medium (Invitro-
gen). The medium was supplemented with 10% fetal calf
serum (Invitrogen). The antibodies against integrin β1
(MAB 2000), integrin α1 (MAB1973) and phosphorylated
tyrosine (4G10) (16–316) were from Millipore (Billerica,
MA). Anti-phosphorylated integrin β1 (Tyr783) (600601)
and (Tyr795) (600501) antibodies were obtained from Bio-
legend (San Diego, CA). Antibody against PRL-3 (clone
318) was from Santa Cruz (Santa Cruz, CA). GADPH
antibody was from Proteintech Group (Chicago, IL). PRL-
3 inhibitor 1-(2-bromobenzyloxy)-4-bromo-2-benzylidene
rhodanine (P0108) was from Sigma (St. Louis, MO). The
tyrosine phosphatase inhibitor (Pervanadate) was freshly
prepared by dissolving sodium orthovanadate (Sigma)
with PBS to 30 mM, adding hydrogen peroxide at 0.18%
(v/v), and incubating for 15 min at room temperature
avoiding light before treating the cells at the final concen-
tration of 100 μM.
Plasmids transfection and RNA interference
The plasmids expressing myc-PRL-3, myc-PRL-3-mt
(cystine 104 was mutated to serine) and GFP-PRL-3 were
described as previously [23]. The small interference RNAs
(siRNAs) targeting integrin α1 and PRL-3 were synthe-
sized by GenePharma (Shanghai, China), the sequence for
integrin α1: sense, 5’- GCCCUUAUAUGCCUAUAGA -3’;
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quence for PRL-3: sense, 5’- CAGCAAGCAGCUCAC
CUAC -3’; antisense, 5’- GUAGGUGAGCUGCUUGCUG
-3’. Plasmids and siRNA were transfected into cells with
Lipofectamine 2000 (Invitrogen) following provider’s
instruction.
Immunofluorescence
To visualize the localization of integrin β1, BGC823 cells
were cultured on the coverslips and fixed with 2% parafor-
maldehyde for 30 min at 4°C, followed by permeabilization
with 0.5% Triton X-100 in PBS for 5 min, and blocking
with 3% bovine serum albumin overnight at 4°C. After in-
cubation with anti-integrin β1 (1: 300) for 1 hr at room
temperature, cells were probed with tetramethyl rhoda-
mine isothiocyanate-conjugated secondary antibody, coun-
terstained with 4', 6-diamidino-2-phenylindole (DAPI), and
mounted on 50% glycerol/PBS. Localization of PRL-3 was
analyzed by transfecting the cells with pEGFP-PRL-3. A
Leica SP2 confocal system (Leica Microsystems, Dresden,
Germany) was used to observe the localization of integrin
β1 and GFP-PRL-3.
Western blotting and immunoprecipitation
For Western blotting, cells were directly lysed in 1x
loading buffer. For immunoprecipitation assay, cells
were homogenized in lysis buffer (50 mM HEPES pH
8.0, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 10%
glycerol, 50 mM NaF, 1 mM Na3VO4, 2 mM dithiothrei-
tol, 1 × protease cocktail (Sigma)) for 20 min at 4°C.
The supernatant was collected after centrifugation at
12,000 × g for 20 min at 4°C and then incubated with
indicated antibodies conjugated to protein G-Sepharose
(Invitrogen). Cell lysates or immunoprecipitates were
separated by SDS-PAGE and electro-blotted to the nitro-
cellulose membranes. Non-specific binding was blocked
with 5% non-fat milk in PBS overnight at 4°C and was
rinsed twice with PBST. Then the membranes were
incubated with indicated primary antibodies at room
temperature for 1.5 h, and washed six times with PBST,
followed by horseradish peroxidase-labeled secondary
antibodies for 45 min and washed again as above. Pro-
tein bands were visualized with enhanced chemolumi-
nescence system (Thermo Scientific, Rockford, IL).
GST Pull-down assay
Deoxyribonucleic acids encoding intracellular domain of
integrin β1 (752-798aa) was amplified by PCR with the
following primers: sense, 5’- GACTGAATTCAAGCTTT
TAATGATAATTCATG -3’; antisense, 5’- AGCAACTC
GAGGTGTTGTGGGATTTGCAC -3’. The PCR product
was digested by EcoR I/Xho I and inserted into pGEX-
4T1 vector. His-tagged PRL-3 was constructed by insert-
ing the digested PRL-3 into pET-28a vector. For pull-down assay, glutathione-Sepharose beads (Invitrogen)
were incubated with E. coli bacteria lysates expressing
GST-integrin β1 or GST. After being washed with PBS,
these beads were incubated with His-PRL-3 in binding
buffer (10 mM Tris–HCl pH 8.0, 150 mM NaCl, 1 mM
dithiothreitol, 1 mM PMSF, 1% Triton X-100, 10% gly-
cerol) for 4 hours at 4°C, then washed three times, boiled
in SDS loading buffer, separated by SDS-PAGE and
immunoblotted with PRL-3 and GST antibodies.
In vitro phosphatase assay
Integrin β1 protein was immunoprecipitated from 1000
μg protein from HCT116 cell lysates with 1 μg integrin
β1 antibody conjugated to protein G-Sepharose. For
control, cell lysates were immunoprecipitated with 1 μg
pre-immune IgG. After being washed 3 times with lysis
buffer, once with dephosphorylation buffer (50 mM Tris
pH 7.5, 2 mM dithiothreitol, 1 mM MgCl2, 0.1 mM
MnCl2), the precipitates were used as substrate for
in vitro phosphatase assay. GST-PRL-3, GST-PRL-3-mt,
and GST (1 μg each) were used as phosphatase and
incubated with substrate in 20 μL dephosphorylation
buffer at 30°C for 30 min. The reaction was stopped by
boiling in 2 × loading buffer and the phosphorylated in-
tegrin β1 was detected by immunoblotting with 4G10
antibody.
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